AU2004272289B2 - Therapeutic binding molecules - Google Patents

Therapeutic binding molecules Download PDF

Info

Publication number
AU2004272289B2
AU2004272289B2 AU2004272289A AU2004272289A AU2004272289B2 AU 2004272289 B2 AU2004272289 B2 AU 2004272289B2 AU 2004272289 A AU2004272289 A AU 2004272289A AU 2004272289 A AU2004272289 A AU 2004272289A AU 2004272289 B2 AU2004272289 B2 AU 2004272289B2
Authority
AU
Australia
Prior art keywords
seq
binding molecule
humanised
variable region
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004272289A
Other languages
English (en)
Other versions
AU2004272289A1 (en
Inventor
Andras Aszodi
Gregorio Aversa
Jose M. Carballido Herrera
Silvia Gregori
Bruce M. Hall
Margit Jeschke
Frank Kolbinger
Veronique Loux
Maria Grazia Roncarolo
Jose W. Saldanha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/666,332 external-priority patent/US20050069538A1/en
Priority claimed from GB0414309A external-priority patent/GB0414309D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2004272289A1 publication Critical patent/AU2004272289A1/en
Application granted granted Critical
Publication of AU2004272289B2 publication Critical patent/AU2004272289B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2004272289A 2003-09-18 2004-09-17 Therapeutic binding molecules Ceased AU2004272289B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/666,332 US20050069538A1 (en) 2003-09-18 2003-09-18 Therapeutic binding molecules
US10/666,332 2003-09-18
GB0414309A GB0414309D0 (en) 2004-06-25 2004-06-25 Organic compounds
GB0414309.5 2004-06-25
PCT/EP2004/010471 WO2005026210A2 (en) 2003-09-18 2004-09-17 Therapeutic binding molecules

Publications (2)

Publication Number Publication Date
AU2004272289A1 AU2004272289A1 (en) 2005-03-24
AU2004272289B2 true AU2004272289B2 (en) 2008-09-18

Family

ID=34315457

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004272289A Ceased AU2004272289B2 (en) 2003-09-18 2004-09-17 Therapeutic binding molecules

Country Status (28)

Country Link
EP (1) EP1664122B1 (enExample)
JP (1) JP4762142B2 (enExample)
KR (1) KR20060079232A (enExample)
AR (2) AR045765A1 (enExample)
AT (1) ATE461219T1 (enExample)
AU (1) AU2004272289B2 (enExample)
BR (1) BRPI0414515A (enExample)
CA (1) CA2537217A1 (enExample)
CY (1) CY1110033T1 (enExample)
DE (1) DE602004026081D1 (enExample)
DK (1) DK1664122T3 (enExample)
EC (1) ECSP066432A (enExample)
ES (1) ES2341341T3 (enExample)
HR (1) HRP20100334T1 (enExample)
IL (1) IL173820A0 (enExample)
IS (1) IS8397A (enExample)
MA (1) MA28041A1 (enExample)
MY (1) MY143963A (enExample)
NO (1) NO20061681L (enExample)
NZ (1) NZ545605A (enExample)
PE (1) PE20060019A1 (enExample)
PL (1) PL1664122T3 (enExample)
PT (1) PT1664122E (enExample)
RU (1) RU2386639C2 (enExample)
SI (1) SI1664122T1 (enExample)
TN (1) TNSN06087A1 (enExample)
TW (1) TW200521231A (enExample)
WO (1) WO2005026210A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2502631A1 (en) 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immune suppressor and its use
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
TWI579722B (zh) * 2015-02-17 2017-04-21 陳沛隆 藥物不良反應風險評估方法及其裝置
WO2016164502A1 (en) 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
JP2019522050A (ja) * 2016-06-17 2019-08-08 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 細胞の枯渇のための組成物および方法
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
KR20200094181A (ko) 2017-11-29 2020-08-06 마젠타 테라퓨틱스 인코포레이티드 Cd5+ 세포를 고갈시키기 위한 조성물 및 방법
WO2022020583A1 (en) * 2020-07-24 2022-01-27 The Board Of Trustees Of The Leland Standford Junior University Compositions and methods for modulation of sirpalpha-mediated signaling
WO2022079199A1 (en) 2020-10-15 2022-04-21 UCB Biopharma SRL Binding molecules that multimerise cd45
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
US20250041339A1 (en) 2021-11-19 2025-02-06 The Trustees Of The University Of Pennsylvania Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell Therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011918A1 (en) * 1996-09-18 1998-03-26 Research Corporation Technologies, Inc. Use of antibodies to cd45r leukocyte antigens for immunomodulation
WO2002072832A2 (en) * 2001-02-12 2002-09-19 Novartis Ag Therapeutic binding molecules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG67924A1 (en) * 1991-07-25 1999-10-19 Idec Pharma Corp Recombinant antibodies for human therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011918A1 (en) * 1996-09-18 1998-03-26 Research Corporation Technologies, Inc. Use of antibodies to cd45r leukocyte antigens for immunomodulation
WO2002072832A2 (en) * 2001-02-12 2002-09-19 Novartis Ag Therapeutic binding molecules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Aversa, G. et al., Cellular Immunology (1994) 158(2): 314-328 *
Aversa, G. G et al., Transplantation Proceedings (1989) 21(1): 349-350 *
Gregori et al., The FASEB Journal (2003) 17(7): Page C63, abstract 37.23 *

Also Published As

Publication number Publication date
ATE461219T1 (de) 2010-04-15
CY1110033T1 (el) 2015-01-14
WO2005026210A3 (en) 2005-07-14
TNSN06087A1 (en) 2007-10-03
DE602004026081D1 (de) 2010-04-29
NZ545605A (en) 2009-03-31
MY143963A (en) 2011-07-29
JP4762142B2 (ja) 2011-08-31
EP1664122B1 (en) 2010-03-17
AR079458A2 (es) 2012-01-25
WO2005026210A2 (en) 2005-03-24
ECSP066432A (es) 2006-09-18
HK1091844A1 (en) 2007-01-26
IL173820A0 (en) 2006-07-05
PE20060019A1 (es) 2006-02-27
IS8397A (is) 2006-04-03
BRPI0414515A (pt) 2006-11-07
MA28041A1 (fr) 2006-07-03
SI1664122T1 (sl) 2010-07-30
KR20060079232A (ko) 2006-07-05
ES2341341T3 (es) 2010-06-18
CA2537217A1 (en) 2005-03-24
AR045765A1 (es) 2005-11-09
PT1664122E (pt) 2010-05-10
NO20061681L (no) 2006-06-13
DK1664122T3 (da) 2010-06-28
HRP20100334T1 (hr) 2010-07-31
TW200521231A (en) 2005-07-01
RU2386639C2 (ru) 2010-04-20
PL1664122T3 (pl) 2010-08-31
AU2004272289A1 (en) 2005-03-24
JP2007529196A (ja) 2007-10-25
EP1664122A2 (en) 2006-06-07
RU2006112598A (ru) 2007-10-27

Similar Documents

Publication Publication Date Title
AU2004272289B2 (en) Therapeutic binding molecules
KR20100035643A (ko) 성숙 수지상 세포에서의 허용유발 표현형의 유도
ZA200601418B (en) Therapeutic binding molecules
KR100752029B1 (ko) 치료용 결합 분자
AU2022200108C1 (en) Chimeric receptors to FLT3 and methods of use thereof
CN109414455B (zh) Bcma结合分子及其使用方法
KR102120815B1 (ko) 키메라 수용체 및 그의 사용 방법
MXPA06003128A (en) Therapeutic binding molecules
AU2006203778B2 (en) Therapeutic binding molecules
AU2002231795A1 (en) Therapeutic binding molecules
HK1071769B (en) Therapeutic binding molecules
HK1091844B (en) Therapeutic humanised antibodies against cd45 isoforms

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired